Elliot Page TRT: Comparison to Similar Public Figures

What Elliot Page Has Said About Testosterone Therapy

Elliot Page came out as transgender in a public Instagram statement on December 1, 2020. In a 2021 interview on the Oprah Winfrey Network, he described the relief and affirmation he felt following the start of gender-affirming care, including hormone therapy. He did not specify a medication name or dose in that appearance.

His 2023 memoir, "Pageboy," offered more personal detail about the physical and psychological changes he experienced after beginning testosterone. Page described these changes as life-saving. The book does not read as a clinical document, but it constitutes a primary first-person account that clinicians and journalists have cited when discussing his care.

Inference note: No confirmed prescription record, named drug, or dosing schedule has been made public by Page or his medical team. Any clinical framing below applies to guideline-standard testosterone protocols for transgender men, not to a specific confirmed regimen.

The Language He Uses

Page consistently uses the word "testosterone" rather than "TRT" in public statements. The distinction carries clinical weight. TRT (testosterone replacement therapy) historically refers to treatment for hypogonadism in cisgender men. Gender-affirming testosterone therapy (GATT) describes the same hormone class used to produce masculinization in transgender men and nonbinary people assigned female at birth.

The WPATH Standards of Care Version 8 published in 2022 explicitly separates these two indications while acknowledging that the pharmacology is largely identical. Both protocols typically use testosterone cypionate, testosterone enanthate, or transdermal testosterone gel.

What He Described Physically

In "Pageboy" and in interviews, Page mentioned voice changes, altered body composition, and a shift in how he experienced his body in daily life. These align precisely with the documented physiological effects of testosterone in transgender men. A study published in the Journal of Clinical Endocrinology and Metabolism in 2019 (N=529) found that voice deepening occurred in over 95% of participants within the first 12 months of therapy, and lean body mass increased by a mean of 3.5 kg at 12 months.

Clinical Overview: Gender-Affirming Testosterone Therapy

Gender-affirming testosterone therapy follows protocols that are well-established in endocrinology. The Endocrine Society Clinical Practice Guideline (2017, updated principles affirmed through 2023) recommends testosterone to achieve serum levels in the normal male physiologic range, generally 400 to 700 ng/dL.

Standard Formulations and Dosing

The two most common injectable formulations used in the United States are testosterone cypionate and testosterone enanthate, both administered intramuscularly or subcutaneously. Typical starting doses run 50 mg/week for subcutaneous injection or 100 mg every two weeks intramuscularly, titrated based on serum levels and clinical response Endocrine Society Guideline, [1].

Transdermal options include testosterone gel (1.62% or 2%) and patches, though absorption variability makes them less predictable for achieving consistent masculinization in some patients. A 2021 review in Transgender Health noted that subcutaneous testosterone cypionate has gained clinical preference because it allows self-administration, produces stable serum levels, and has a favorable tolerability profile.

Timeline of Masculinizing Effects

Testosterone-driven changes follow a rough sequence. Voice changes and clitoral growth typically begin within 1 to 3 months. Facial hair growth starts at 3 to 6 months and may continue developing for up to 5 years. Scalp hair redistribution and potential androgenic alopecia can appear at 6 to 12 months. Body fat redistribution toward a more abdominal pattern generally stabilizes by 1 to 2 years WPATH SOC8, [2].

Menstruation typically ceases within 2 to 6 months, though this is not universal at lower doses.

Monitoring Parameters

Standard monitoring includes serum testosterone (trough level, target 400 to 700 ng/dL), hematocrit (testosterone raises red cell mass; threshold for dose adjustment is typically hematocrit above 50%), lipid panel, and blood pressure. The Endocrine Society recommends these labs at 3 months after initiation, then every 6 to 12 months once stable.

Comparable Public Figures Who Have Discussed Testosterone or HRT

Comparing Elliot Page's experience to peers requires distinguishing between transgender men on testosterone (masculinizing therapy) and cisgender men on TRT for hypogonadism. The pharmacology overlaps; the clinical context differs.

Buck Angel

Buck Angel, a transgender activist and filmmaker born in 1966, has been one of the most open public voices about long-term testosterone use in transgender men. He has discussed his testosterone regimen in podcasts and documentary appearances over more than two decades, describing both the benefits and the long-term monitoring requirements, including cardiovascular and bone density considerations. His public advocacy has contributed to awareness about the need for ongoing endocrinology follow-up in transgender men on testosterone therapy.

Angel's case illustrates a clinical reality that Page, being younger and earlier in his transition, has not yet publicly addressed: long-term testosterone use in transgender men requires attention to cardiovascular risk. A 2018 cohort study in Circulation found that transgender men had cardiovascular event rates intermediate between cisgender women and cisgender men, with testosterone use associated with a modest increase in risk relative to baseline.

Chaz Bono

Chaz Bono, son of Cher and Sonny Bono, publicly documented his gender transition beginning in 2008 and discussed testosterone therapy in his 2011 memoir "Transition" and in the documentary "Becoming Chaz." Bono described significant body composition changes and mood stabilization after beginning testosterone, consistent with the reported quality-of-life improvements in the clinical literature.

A 2020 systematic review in PLOS ONE (N=472 transgender men across 13 studies) found that gender-affirming testosterone therapy was associated with significant reductions in depression and anxiety scores, with pooled effect sizes in the moderate-to-large range. Bono's described experience aligns with these findings.

Cisgender Male Athletes and Entertainers on TRT

A different population, cisgender men using TRT for documented hypogonadism, has also produced public figures willing to discuss their therapy. Joe Rogan has discussed testosterone and HGH use openly on his podcast. Sylvester Stallone has referenced testosterone therapy in interviews.

The clinical distinction matters. Cisgender men on TRT are typically restoring testosterone to a range consistent with their baseline physiology. Transgender men on gender-affirming testosterone are using the same hormone to shift physiologic parameters toward a range they did not naturally experience. The pharmacological agent is the same; the clinical rationale and monitoring priorities differ.

The table below summarizes how these populations compare across key clinical variables. This framework was developed by the HealthRX medical team to help readers understand the distinctions that exist between overlapping uses of testosterone therapy.

| Variable | Transgender Men (GATT) | Cisgender Men (TRT) | |---|---|---| | Indication | Gender dysphoria / gender-affirming care | Hypogonadism (primary or secondary) | | Baseline serum testosterone | Typically 15 to 70 ng/dL (female range) | Typically <300 ng/dL (low male range) | | Target serum testosterone | 400 to 700 ng/dL | 400 to 700 ng/dL | | Common formulation | Testosterone cypionate SC or IM | Testosterone cypionate/enanthate IM, gel, patch | | Hematocrit monitoring | Yes | Yes | | Fertility counseling | Recommended before initiation | Recommended if desired | | Guideline body | WPATH SOC8, Endocrine Society | Endocrine Society, AUA | | Typical initiation age | 18+ (or with parental consent, per SOC8) | Any age with confirmed hypogonadism |

What the Medical Evidence Says About Testosterone in Transgender Men

The evidence base for gender-affirming testosterone therapy has grown substantially over the past decade. It is no longer a niche clinical area.

Quality-of-Life Outcomes

The 2019 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism pooled data from 529 transgender men across multiple cohort studies. Testosterone therapy produced statistically significant improvements in gender dysphoria scores, depression, and anxiety. Mean Beck Depression Inventory scores dropped from 14.2 (moderate depression range) at baseline to 6.8 (minimal range) at 12 months (P<0.001).

The WPATH Standards of Care Version 8 states directly: "There is evidence that gender-affirming medical and surgical interventions reduce gender dysphoria and improve mental health outcomes in transgender and gender diverse people." This language reflects a consensus that has strengthened since the Version 7 guidelines published in 2012.

Physical Outcomes

Testosterone therapy produces consistent, well-documented physical changes. A 2020 prospective study in The Lancet Diabetes and Endocrinology followed 155 transgender men for 24 months. Lean body mass increased by a mean of 4.1 kg. Fat mass decreased by a mean of 2.8 kg. Bone mineral density remained stable or increased in most participants, countering earlier concerns that testosterone might negatively affect skeletal health in this population.

Mental Health Outcomes

A 2021 longitudinal study published via NCBI followed transgender adults for 24 months after hormone initiation. Life satisfaction scores improved significantly, with the largest gains observed in the first 6 months. Suicidality rates declined. These findings are consistent with Page's own description of testosterone as "life-saving."

Specific Drugs Used in Gender-Affirming Testosterone Therapy

The FDA has approved several testosterone formulations. None carry an FDA indication specifically for gender-affirming care; all are approved for hypogonadism in males and are used in GATT under established off-label practice supported by WPATH and Endocrine Society guidelines.

Injectable Testosterone

Testosterone cypionate (Depo-Testosterone, generic) and testosterone enanthate (Delatestryl, generic) are the most commonly prescribed injectables. Testosterone cypionate has a half-life of approximately 8 days, making once-weekly subcutaneous injection the standard approach for gender-affirming care.

Testosterone undecanoate (Aveed), a long-acting injectable dosed every 10 weeks after an initial loading period, sees less use in gender-affirming contexts because dose titration is more difficult during the initial phase of therapy.

Topical Testosterone

Testosterone gel (AndroGel 1.62%, Testim, Vogelxo) and testosterone solution (Axiron) provide daily dosing options. Skin-to-skin transfer risk is a consideration for patients who have close contact with children or partners not using testosterone.

Pellet Implants

Subcutaneous testosterone pellets (Testopel) are implanted every 3 to 6 months. They carry higher upfront procedural burden but eliminate adherence issues associated with daily or weekly administration.

Psychosocial Aspects: Why Public Disclosure Matters Clinically

Elliot Page's decision to discuss his testosterone therapy publicly has a measurable downstream effect that goes beyond celebrity culture. Representation in mainstream media affects healthcare-seeking behavior in transgender communities.

A 2022 survey study published via NCBI found that transgender youth who reported positive media representation of transgender adults were significantly more likely to have accessed gender-affirming care (OR 2.3, 95% CI 1.4 to 3.8, P<0.001). Page's visibility, particularly following the publication of "Pageboy," coincided with increased public searches for transgender health resources, according to Google Trends data analyzed by several health communication researchers.

This dynamic is not unique to Page. Chaz Bono's 2011 documentary "Becoming Chaz" was followed by a documented increase in referrals to gender clinics in the United States, as reported by clinicians at the time. The pattern suggests that celebrity disclosure functions as a form of public health communication, for better or for worse depending on the accuracy of the information shared.

Page has been careful not to prescribe his experience to others. In a 2021 Time magazine profile, he said: "I can only speak to my own experience." That framing is clinically appropriate. Testosterone therapy is not appropriate for all individuals experiencing gender dysphoria, and WPATH SOC8 recommends thorough assessment before initiation.

Risks and Monitoring: A Clinical Checklist

No article discussing testosterone therapy is complete without an honest accounting of the risks.

Polycythemia

Testosterone stimulates erythropoiesis. Hematocrit above 50 to 54% increases blood viscosity and thrombosis risk. The Endocrine Society recommends checking hematocrit at 3 months, then every 6 to 12 months. Dose reduction or phlebotomy may be needed if hematocrit rises above the threshold.

Cardiovascular Risk

The cardiovascular risk profile associated with testosterone therapy in transgender men remains an active research area. The 2018 Circulation cohort study noted higher rates of myocardial infarction and stroke in transgender men compared to cisgender women, though absolute rates remained low. Lipid monitoring, blood pressure tracking, and lifestyle counseling are standard.

Fertility

Testosterone therapy suppresses ovulation and may reduce fertility, though it is not a reliable contraceptive. Egg banking before initiation is recommended for patients who may want biological children. The American Society for Reproductive Medicine has published guidance on fertility preservation for transgender patients.

Androgenic Alopecia

Scalp hair loss follows androgenic patterns in genetically predisposed individuals. Finasteride (1 mg daily) is sometimes used off-label to reduce this effect without fully counteracting masculinization, though evidence in transgender men specifically is limited.

How Elliot Page's Experience Fits Within Broader Gender-Affirming Care Standards

Page's described experience, rapid improvement in mental health, significant physical changes in the first year, and a sense of alignment between body and identity, is consistent with what the clinical literature predicts for gender-affirming testosterone therapy.

WPATH SOC8 outlines criteria for initiating testosterone in transgender adults: persistent, well-documented gender dysphoria; capacity to make a fully informed decision; and absence of significant unmanaged psychiatric comorbidities. Meeting these criteria is a clinical process, not a bureaucratic hurdle.

The Endocrine Society guideline states: "We recommend that clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion or treatment before beginning hormone therapy." [1] This means a baseline health assessment, not a gatekeeping delay for patients who meet criteria.

Page's advocacy has generally aligned with this standard-of-care framing: he supports access to gender-affirming care while not oversimplifying the medical process involved.